P

Pfizer

Makes cancer drugs, vaccines and other medicines

Medical Affairs Dermatology

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Master's, PhD, MD
Tokyo, Japan
Hybrid
Biology & Biotech

About the job

Requirements
  • A four-year university undergraduate degree and a master's degree in life science, or a pharmacist qualification with a four-year university degree and master's degree or equivalent life science research experience, or a six-year university degree with a pharmacist license, or a master's degree or above for nurses, or qualifications as a veterinarian, dentist, or MD.
  • Medical and pharmaceutical expert knowledge of the therapeutic disease area and products.
  • Ability to communicate appropriately and build good relationships with internal and external stakeholders.
  • Ability to work effectively with teams and across functions, demonstrate Pfizer's Values & Behaviors, and learn from others.
  • Ability to conduct medical discussions with relevant departments and external healthcare professionals.
  • Understanding of compliance and relevant pharmaceutical industry laws and regulations, and advocacy for appropriate product use.
  • Knowledge of the internal organization structure, key stakeholders, and strategies.
  • Ability to quickly acquire necessary medical and scientific knowledge and skills through self-learning.
  • Clinical research experience.
  • Ability to understand written and spoken English and Japanese in the assigned therapeutic disease area and scientific interactions.
Responsibilities
  • Serve as Pfizer Japan's medical scientific point of contact for healthcare professionals, medical societies, regulators, academia, and other external stakeholders.
  • Maintain scientific standards, independence, and compliance in external medical and scientific activities and relevant internal processes.
  • Build collaborative scientific relationships through non-promotional exchanges, including discussion of current research and follow-up on academic conference presentations, with dermatology stakeholders.
  • Develop and maintain stakeholder maps to identify relevant healthcare professionals, medical societies, and external stakeholders.
  • Handle unsolicited medical requests, provide accurate, high-quality, unbiased information as permitted by Pfizer policies, and share customer viewpoints with Pfizer as appropriate.
  • Follow up on clinical investigator-sponsored research and medical grants in compliance with Pfizer policies.
  • Acquire medical and pharmaceutical information and current scientific knowledge in the assigned area.
  • Deliver medical-plan activities, including educational materials, real-world evidence generation, non-interventional and database studies, registries in collaboration with the Health & Value team, and timely publication of data.
  • Provide medical and scientific information to and from medical institutions and other relevant sources and stakeholders.
  • Promote understanding of the clinical and medical attributes of products to support their safe and efficacious use.
  • Maintain scientific standards and provide medical and scientific expertise in internal and external activities.
  • Contribute to local medical strategies and life-cycle clinical plans for inline and pipeline medicines and vaccines to address unmet medical needs and data gaps.
  • Contribute to medical strategy decisions for assigned products to support their safe, proper, and effective use and address patient, healthcare professional, and clinical study needs.
  • Contribute to department and team goals, participate as a core member in cross-organizational projects, and guide delivery of results.
  • Support team and organizational members, in coordination with the line manager, to advance team goals.
  • Identify unmet medical needs and healthcare disparities in assigned assets and therapeutic areas through advisory boards, scientific exchanges, and other medical activities.
  • Create activity plans with senior Medical management to address needs and fill data gaps.
  • Develop and execute Customer Facing Medical Plans for assigned therapeutic areas and assets, including scientific communications, advisory boards, educational seminars, data-generation initiatives, medical materials, and scientific input.
  • Provide subject-matter expertise and scientific exchange, bringing stakeholder insights into the organization to help shape strategy.
  • Build and maintain long-term peer-to-peer scientific relationships with leading healthcare professionals and specialists, including non-traditional partners and key decision makers.
  • Maintain and enhance cross-business-unit alignment on metrics.
  • Gather and analyze information and insights before meetings with stakeholders and healthcare professionals.
  • Provide stakeholder and healthcare professional feedback to relevant company departments and consolidate it into medical, public health, and healthcare insights.
  • Promote evidence generation based on medical needs through constructive partnerships with internal and external stakeholders.
  • Apply health literacy and cultural awareness principles to patient-centered medical communications and deliverables.
  • Provide stakeholder and healthcare professional feedback on product life-cycle strategies to relevant company divisions and departments.
  • Collect and analyze unmet medical needs and seek solutions with cross-functional colleagues.
  • Provide scientific input for scientific meetings and materials.
  • Provide medical education programs with and to relevant stakeholders.
  • Conduct activities in compliance with Japanese Ministry of Health, Labour and Welfare guidelines for prescription drug sales information activities and all applicable policies, guidelines, and regulations.
  • Gather and report safety information for Pfizer products in accordance with applicable laws, regulations, and Pfizer policy, and attend assigned safety-reporting training at the appropriate time.
  • In collaboration with Japan Medical leadership, Global Medical Affairs members, and relevant functions, identify unmet medical needs and candidate therapies for potential medical interventions in Japan through advisory boards and consultations with medical experts while maintaining confidentiality.
  • Respond rapidly to critical supply issues from the medical perspective, including communications with academic societies and regulatory authorities.
Desired Qualifications
  • Medical Affairs, Development, or Research work experience.
  • Scientific publication experience.
  • Medical science liaison experience.
  • MD with clinical experience; board certification is preferred.
  • PhD in Life Science.
  • A minimum TOEIC score of 730.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.

Business Wire
Oct 7th, 2026
Pfizer's TUKYSA wins FDA approval for front-line HER2+ metastatic breast cancer maintenance treatment

The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.

Yahoo Finance
Oct 7th, 2026
Buffett indicator hits 235.8% as Oracle warns investors 'playing with fire' — 3 undervalued stocks to buy

Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.